Extended-release physostigmine in Alzheimer disease: A multicenter, double-blind, 12-week study with dose enrichment

Archives of General Psychiatry

Volumn 57, Issue 2, 2000, Pages 157-164

  Van Dyck, Christopher H ^a   Newhouse, Paul ^b   Falk, William E ^c   Mattes, Jeffrey A ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Psychopharmacology Res Assoc P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; PHYSOSTIGMINE SALICYLATE; PLACEBO; SYNAPTON; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; ERUCTATION; FEMALE; HALLUCINATION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; SWEATING; THORAX PAIN; VERTIGO; VOMITING;

EID: 0033979355     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.2.157     Document Type: Article

References (34)

1. Brumback RA, Leech RW. Alzheimer's disease: pathophysiology and the hope for therapy. J Okla State Med Assoc. 1994;87:103-111.
2. Ernst R, Hay J. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health, 1994;84:1261-1264.
3. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122-126.
4. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237-1239.
5. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459.
6. Bartus RT, Dean RL, Tetrahydroaminoacridine, 3,4-diaminopyridine and physostigmine: direct comparison of effects on memory in aged primates. Neurobiol Aging. 1988;9:351-356.
7. Bartus RT. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav. 1978; 9:833-836.
8. Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmme without lecithin improved memory in Alzheimer's disease. J Am Geriatr Soc. 1989; 37:42-48.
9. Mohs RC, Davis BM, Johns CA, Mathé AA, Greenwald BS, Horvath TB, Davis KL. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry. 1985;142:28-33.
10. Stern Y, Sano M, Mayeux R. Effects of oral physostigmine in Alzheimer's disease. Ann Neurol. 1987;220:306-310.
11. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med. 1992;327:1253-1259.
12. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of lacrine in Alzheimer's disease. JAMA. 1992;268:2523-2529.
13. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991.
14. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
15. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology. 1998;50:1214-1221.
16. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1: 55-65.
17. Thal LJ, Lasker B, Sharpless NS, Bobotas G, Schor JM, Nigalye A. Plasma physostigmine concentrations after controlled-release oral administration [letter]. Arch Neurol. 1989;46:13.
18. Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology. 1996;47:1389-1395.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. neurology. 1384;34:939-944.
20. Folstein MF, Fostein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
21. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7:486-488.
22. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
23. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology. 1994;44:2315-2321.
24. Clinical Global Impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rev ed. Rockville, Md: Dept of Health, Education and Welfare: 1976:218-222. Dept of Health, Education and Welfare publication ADM 76-338.
25. Lawton MP, Brody EM. Assessment of older people: self-monitoring and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
26. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
27. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials Biometrics. 1979;35:549-556.
28. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-664.
29. Kramer-Ginsberg E, Mohs RC, Aryan M, Lobel D, Silverman J, Davidson M, Davis KL. Clinical predictors of course for Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharmacol Bull. 1988;24:458-462.
30. Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week randomized trial of controlled-release physostigrnine in patients with Alzheimer's disease. Neurology. 1999;52:1146-1152.
31. Rogers SL, Friedhoff LT, and the Donepezil Study Group The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303.
32. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. neurology. 1998;50:1222-1230.
33. Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. Arch Intern Med. 1995;155:1766-1772.
34. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther. 1989;11:545-554.